Metadon Martindale Pharma 2 mg/ ml Norveç - Norveççe - Statens legemiddelverk

metadon martindale pharma 2 mg/ ml

ethypharm (2) - metadonhydroklorid - mikstur, oppløsning - 2 mg/ ml

Tramagetic OD 300 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic od 300 mg

mundipharma as - tramadolhydroklorid - depottablett - 300 mg

Tramagetic OD 150 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic od 150 mg

mundipharma as - tramadolhydroklorid - depottablett - 150 mg

Tramagetic OD 200 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic od 200 mg

mundipharma as - tramadolhydroklorid - depottablett - 200 mg

Tramagetic Retard 100 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic retard 100 mg

mundipharma as - tramadolhydroklorid - depottablett - 100 mg

Tramagetic Retard 75 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic retard 75 mg

mundipharma as - tramadolhydroklorid - depottablett - 75 mg

Tramagetic Retard 150 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic retard 150 mg

mundipharma as - tramadolhydroklorid - depottablett - 150 mg

Tramagetic Retard 200 mg Norveç - Norveççe - Statens legemiddelverk

tramagetic retard 200 mg

mundipharma as - tramadolhydroklorid - depottablett - 200 mg

Mhyosphere PCV ID Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - griser - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Porcilis PCV ID Avrupa Birliği - Norveççe - EMA (European Medicines Agency)

porcilis pcv id

intervet international b.v. - porcine circovirus type 2 orf2 subunit antigen - immunologicals for suidae, inactivated viral vaccines - griser - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.